Association Between CD47 Expression, Clinical Characteristics and Prognosis in Patients with Advanced Non-small Cell Lung Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2020 Feb 12

PMID 32043750

Citations 33

Authors

Oscar Arrieta

Alejandro Aviles-Salas

Mario Orozco-Morales

Norma Hernandez-Pedro

Andres F Cardona

Luis Cabrera-Miranda

Pedro Barrios-Bernal

Giovanny Soca-Chafre

Graciela Cruz-Rico

Maria de Lourdes Pena-Torres

Guadalupe Moncada-Claudio

Laura-Alejandra Ramirez-Tirado

Affiliations

Soon will be listed here.

Abstract

Objective: CD47 is an antiphagocytic molecule that contributes to tumor cell resistance in host immune surveillance. CD47 overexpression correlated with tumor progression and shorter survival in lung cancer. However, the expression and functional significance of CD47 in Non-Small Cell Lung Cancer (NSCLC) has not been completely understood.

Materials And Methods: In this retrospective study, CD47 expression was immunohistochemically examined in tumor biopsies from 169 NSCLC patients. The association of CD47 levels (H-score) with clinicopathological characteristics and survival outcomes was evaluated.

Results: CD47 protein was detected in 84% of patients with a median expression of 80% (0-100). Tumor CD47 levels above 1% and 50% were found in 84% and 65.7% of patients, respectively. While, median CD47 staining index was 160 (0-300). Patients were divided into two groups according to CD47 expression (high or low), using a cutoff value of 150. High CD47 expression was associated with wood smoke exposure (71.1% vs 28.9%, P = .013) and presence of EGFR (+) mutations (66.7% vs 33.3%, P = .04). Survival analysis carried out in the whole population did not show any association of CD47 expression and survival outcome. However, in patients with EGFR (+) mutations, CD47 expression was associated with higher progression-free survival (PFS) (12.2 vs. 4.4 months, P = .032). When the survival analysis was performed according to CD47 levels (cut off value: 150), both, PFS and overall survival (OS) were shortened in patients with a high expression of CD47 (10.7 vs. NR, P = .156) and (29.2 vs. NR months P = .023), respectively.

Conclusions: CD47 overexpression is not a prognostic factor for PFS and OS in NSCLC patients. However, the presence of EGFR mutations and high expression of CD47 were associated with shortened PFS and OS. Coexpression of these markers represents a potential biomarker and characterizes a therapeutic niche for lung cancer.

Citing Articles

Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity.

Li Z, Li M, Yang L, Chen J, Ye Q, Qian W J Immunother Cancer. 2025; 12(12.

PMID: 39794937 PMC: 11667295. DOI: 10.1136/jitc-2024-009473.

Nicotinamide N-methyltransferase negatively regulates metastasis-promoting property of cancer-associated fibroblasts in lung adenocarcinoma.

Wang P, Wang G, Li H, Yuan Y, Chen H, Wang S Cancer Commun (Lond). 2024; 45(2):110-137.

PMID: 39623600 PMC: 11833673. DOI: 10.1002/cac2.12633.

and Are Colinear Genes That Are Highly Coexpressed in Most Cancers and Exhibit Parallel Cancer-Specific Correlations with Survival.

Dong K, Nihal R, Meyer T, Singh S, Kaur S, Roberts D Int J Mol Sci. 2024; 25(16).

PMID: 39201643 PMC: 11354933. DOI: 10.3390/ijms25168956.

Deciphering the role of CD47 in cancer immunotherapy.

Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P J Adv Res. 2024; 63:129-158.

PMID: 39167629 PMC: 11380025. DOI: 10.1016/j.jare.2023.10.009.

Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer.

Saha T, Fojtu M, Nagar A, Thurakkal L, Srinivasan B, Mukherjee M Sci Adv. 2024; 10(24):eadi2046.

PMID: 38875335 PMC: 11177938. DOI: 10.1126/sciadv.adi2046.

References

Arrieta O, Aviles-Salas A, Orozco-Morales M, Hernandez-Pedro N, Cardona A, Cabrera-Miranda L . Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med. 2020; 9(7):2390-2402. PMC: 7131854. DOI: 10.1002/cam4.2882. View

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K . Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11:943-953. PMC: 6345192. DOI: 10.2147/CMAR.S187317. View

OByrne K, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens U . Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011; 12(8):795-805. DOI: 10.1016/S1470-2045(11)70189-9. View

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v1-v27. DOI: 10.1093/annonc/mdw326. View

Chao M, Tang C, Pachynski R, Chin R, Majeti R, Weissman I . Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011; 118(18):4890-901. PMC: 3208297. DOI: 10.1182/blood-2011-02-338020. View

Hang Q, Isaji T, Hou S, Zhou Y, Fukuda T, Gu J . N-Glycosylation of integrin α5 acts as a switch for EGFR-mediated complex formation of integrin α5β1 to α6β4. Sci Rep. 2016; 6:33507. PMC: 5027594. DOI: 10.1038/srep33507. View

Yang Y, Guo R, Chen Q, Liu Y, Zhang P, Zhang Z . A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index. Biotechnol Lett. 2018; 40(5):789-795. DOI: 10.1007/s10529-018-2535-2. View

Migliaccio C, Kobos E, King Q, Porter V, Jessop F, Ward T . Adverse effects of wood smoke PM(2.5) exposure on macrophage functions. Inhal Toxicol. 2013; 25(2):67-76. PMC: 4757468. DOI: 10.3109/08958378.2012.756086. View

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

10.

Pirker R, Pereira J, von Pawel J, Krzakowski M, Ramlau R, Park K . EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011; 13(1):33-42. DOI: 10.1016/S1470-2045(11)70318-7. View

11.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

12.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Chirieac L . Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(4):504-535. DOI: 10.6004/jnccn.2017.0050. View

13.

Zhao C, Yu S, Wang S, Li S, Wang Z, Han S . Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer. Oncol Lett. 2018; 15(2):2017-2023. PMC: 5774548. DOI: 10.3892/ol.2017.7447. View

14.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

15.

Lastwika K, Wilson 3rd W, Li Q, Norris J, Xu H, Ghazarian S . Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res. 2015; 76(2):227-38. DOI: 10.1158/0008-5472.CAN-14-3362. View

16.

Kaur S, Elkahloun A, Singh S, Chen Q, Meerzaman D, Song T . A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget. 2016; 7(9):10133-52. PMC: 4891109. DOI: 10.18632/oncotarget.7100. View

17.

Zhao H, Wang J, Kong X, Li E, Liu Y, Du X . CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. Sci Rep. 2016; 6:29719. PMC: 4944213. DOI: 10.1038/srep29719. View

18.

Casey S, Tong L, Li Y, Do R, Walz S, Fitzgerald K . MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016; 352(6282):227-31. PMC: 4940030. DOI: 10.1126/science.aac9935. View

19.

Barrera L, Montes-Servin E, Hernandez-Martinez J, Garcia-Vicente M, Montes-Servin E, Herrera-Martinez M . CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients. Br J Cancer. 2017; 117(3):385-397. PMC: 5537491. DOI: 10.1038/bjc.2017.173. View

20.

Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T . Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014; 25(10):1935-1940. DOI: 10.1093/annonc/mdu242. View